Abstract
Objectives
To investigate whether 3D phase-resolved functional lung (PREFUL)-MRI parameters are suitable to measure response to elexacaftor/tezacaftor/ivacaftor (ETI) therapy and their association with clinical outcomes in cystic fibrosis (CF) patients.
Methods
Twenty-three patients with CF (mean age: 21; age range: 14–46) underwent MRI examination at baseline and 8–16 weeks after initiation of ETI. Morphological and 3D PREFUL scans assessed pulmonary ventilation. Morphological images were evaluated using a semi-quantitative scoring system, and 3D PREFUL scans were evaluated by ventilation defect percentage (VDP) values derived from regional ventilation (RVent) and cross-correlation maps. Improved ventilation volume (IVV) normalized to body surface area (BSA) between baseline and post-treatment visit was computed. Forced expiratory volume in 1 second (FEV1) and mid-expiratory flow at 25% of forced vital capacity (MEF25), as well as lung clearance index (LCI), were assessed. Treatment effects were analyzed using paired Wilcoxon signed-rank tests. Treatment changes and post-treatment agreement between 3D PREFUL and clinical parameters were evaluated by Spearman’s correlation.
Results
After ETI therapy, all 3D PREFUL ventilation markers (all p < 0.0056) improved significantly, except for the mean RVent parameter. The BSA normalized IVVRVent was significantly correlated to relative treatment changes of MEF25 and mucus plugging score (all |r| > 0.48, all p < 0.0219). In post-treatment analyses, 3D PREFUL VDP values significantly correlated with spirometry, LCI, MRI global, morphology, and perfusion scores (all |r| > 0.44, all p < 0.0348).
Conclusions
3D PREFUL MRI is a very promising tool to monitor CFTR modulator–induced regional dynamic ventilation changes in CF patients.
Clinical relevance statement
3D PREFUL MRI is sensitive to monitor CFTR modulator–induced regional ventilation changes in CF patients. Improved ventilation volume correlates with the relative change of mucus plugging, suggesting that reduced endobronchial mucus is predominantly responsible for regional ventilation improvement.
Key Points
• 3D PREFUL MRI–derived ventilation maps show significantly reduced ventilation defects in CF patients after ETI therapy.
• Significant post-treatment correlations of 3D PREFUL ventilation measures especially with LCI, FEV1 %pred, and global MRI score suggest that 3D PREFUL MRI is sensitive to measure improved regional ventilation of the lung parenchyma due to reduced inflammation induced by ETI therapy in CF patients.
• 3D PREFUL MRI–derived improved ventilation volume (IVV) correlated with MRI mucus plugging score changes suggesting that reduced endobronchial mucus is predominantly responsible for regional ventilation improvement 8–16 weeks after ETI therapy.
Similar content being viewed by others
Explore related subjects
Find the latest articles, discoveries, and news in related topics.Avoid common mistakes on your manuscript.
Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disorder of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which reduces chloride and sodium ion transport across cell membrane of epithelial barriers. Consequently, the airways are filled with thick mucus that restricts breathing. CF occurs in approximately 1 in 3000–4000 newborns among Caucasians [1]. Thus, early diagnosis and monitoring of therapy is of significant interest. Recently, a new CFTR modulator combination medication, composed of a chloride channel potentiator (ivacaftor) and two CFTR correctors (elexacaftor and tezacaftor), has been introduced to treat CF. The first studies with this triple-combination therapy, henceforth abbreviated ETI, demonstrated significant improvements in clinical outcomes in CF patients [2,3,4].
The ventilation outcomes in CF are routinely measured using spirometry and nitrogen multiple-breath washout (N2-MBW). Both techniques estimate global pulmonary ventilation parameters. However, they cannot assess regional information. Chest CT allows for regional monitoring of early lung disease [5]. In contrast to CT, MRI offers radiation-free imaging and therefore the possibility for follow-up measurements without accumulating radiation exposure.
In the last 15 years, several MRI techniques have been developed to assess regional ventilation during free breathing and without the usage of contrast-agent [6,7,8,9,10]. Among them, 3D phase-resolved functional lung (PREFUL) MRI enables quantitative assessment of pulmonary ventilation during free breathing on a regional level of the total lung volume [11]. In contrast to 2D alternatives, 3D techniques [11,12,13] offer whole lunge coverage (better spatial resolution and likely higher sensitivity for hypoventilated regions) and account for through-plane motion, which potentially improve the quality of functional ventilation maps. 3D PREFUL ventilation parameters have been shown to correlate well with spirometry measurements and showed a good interscan repeatability in a study cohort consisting of healthy volunteers and chronic obstructive pulmonary disease patients [14]. Recently, ETI therapy has been shown to improve global clinical ventilation parameters and semi-quantitative morphologic MRI scoring in CF patients [15]. However, it is unknown whether 3D PREFUL ventilation parameters are sensitive to measure treatment changes in patients with CF.
The objective of this study was to investigate if the ventilation parameters derived by 3D PREFUL are suitable to measure response to ETI therapy and their association with improvements in clinical outcome measures in CF patients.
Materials and methods
Study participants
A total of 23 CF patients (13 female, mean age ± standard deviation (SD), 21.0 ± 9.3 years, mean FEV1 % pred. at baseline 87.8%) were recruited in this prospective observational single-center study. The local ethics committee of Hannover Medical School (8922_B0_S_2020) approved the study and informed written consent was obtained prior to the examination from each study participant and/or their legal guardians. Participants were included when they (1) were older than 12 years, (2) were compound-heterozygous for F508del and a minimal function mutation or homozygous for F508del, and (3) had no prior exposure to ETI. The following exclusion criteria were applied: (1) pulmonary exacerbation at baseline or follow-up, (2) history of solid organ transplantation, (3) pregnancy, (4) claustrophobia, (5) metallic implantations incompatible with MR imaging. Morphological and functional 3D PREFUL MRI, PFT, and N2-MBW were evaluated at baseline and 8–16 weeks after initiation of ETI therapy. The morphological MRI images, spirometry data, and LCI values of the included CF patients have been reported in a previous study [15].
MR protocol
MR examinations were performed on a 1.5-T scanner (MAGNETOM Avanto; Siemens Healthcare). The MR protocol consisted of the following sequences [15]: (1) T2-weighted half-Fourier acquisition single-shot turbo spin echo (HASTE) sequences in axial and coronal orientation, acquired by breath-hold maneuvers; (2) T2-weighted turbo spin echo sequences in PROPELLER technique (BLADE), acquired in axial and coronal orientation by using respiratory navigator triggering; (3) T1-weighted volumetric interpolated breath-hold examination (VIBE) sequences, acquired in axial and coronal orientation. (4) 2D non-contrast-enhanced PREFUL technique to assess lung perfusion and 3D PREFUL technique to asses lung ventilation.
For 3D PREFUL, an 8-min measurement [11] was used to assess regional lung ventilation of the whole lung. The following sequence parameters were used for the 3D PREFUL: echo time (TE) 0.81 ms, repetition time (TR) 1.9 ms, flip angle 3.5°, field of view (FOV) 45 × 45 cm2, matrix size 112 × 112 interpolated to 224 × 224, 52–60 partitions, 6/8 partial Fourier along the partition dimension, pixel bandwidth 1500 Hz/pixel, slice thickness 4 mm interpolated to 2 mm.
MR image analysis
Morphological MR images were evaluated based on a well-established semi-quantitative scoring system [16]. Briefly, the global MRI score consists of morphology score and perfusion score. The morphology score is divided into the following subscores: bronchial wall thickening/bronchiectasis, mucus plugging, abscesses/sacculations, consolidations, and special findings, i.e., pleural affection. The perfusion scores were derived by the subtraction of the baseline images (contrast-free) from the images with maximal contrast in the lung tissue [16]. All subscores including the perfusion score are evaluated for each lobe with values of (a) 0 (no abnormality), (b) 1 (< 50% of the lobe affected), and (c) 2 (≥ 50% of the lobe affected). Considering lingula as a sixth lobe, the global MRI score ranges from 0 (normal lung) to 72 (maximally affected lung).
The dynamically acquired 3D PREFUL data were reconstructed to ~40 breathing phases and each phase was registered towards end-inspiration image [17]. Using 3D PREFUL registered images, ventilation defect maps derived from static regional ventilation (RVent) [18] and dynamic cross-correlation (CC) [9] maps based on previously published thresholds were calculated [14]. CC maps assess the dynamics of ventilation using regional flow-volume loops during tidal breathing. Furthermore, ventilation defect percentage (VDP) percent values were computed from both ventilation defect maps as the number of voxels with ventilation below the threshold divided by the total number of voxels of the segmented lung volume. To analyze the treatment effect on a regional level, morphological images of the second visit were co-registered to the morphological end-inspiratory image of the first visit. The treatment response maps (TRMs) were then calculated by subtracting the ventilation defect map after therapy from the baseline ventilation defect maps. Post-treatment improved ventilation volume (IVVRVent and IVVCC) was calculated as the number of positively changed voxels in TRMs (absolute amount of ventilation defect voxels at baseline measurement which resolved after ETI therapy in the follow-up measurement) multiplied by lung volume in milliliters. Both volumes were normalized to body surface area (BSA) at baseline. For image analysis, the lung parenchyma of the 3D PREFUL baseline end-inspiratory reconstructed image was automatically segmented using a 3D convolutional neuronal network (CNN) and manually corrected if needed. The details of the 3D CNN network were described previously [17].
Lung function testing
Spirometry outcomes (forced expiratory volume in 1 second (FEV1) and mid-expiratory flow at 25% of forced vital capacity (MEF25)) were obtained according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines [19] with global lung function initiative (GLI) reference values [20]. Lung clearance index (LCI) was assessed using the N2-MBW technique according to ATS/ERS guidelines [21].
Statistical analysis
For the 3D PREFUL regional parameters of RVent and CC, mean values and SD values inside lung parenchyma were computed. Further ventilation impairment was assessed using 3D PREFUL by a total lung VDP and post-treatment IVV values in milliliters.
The treatment effect on all derived MRI and clinical outcome parameters was analyzed using paired Wilcoxon signed-rank tests.
Treatment changes and post-treatment agreement between 3D PREFUL and clinical parameters were evaluated using Spearman’s correlation (r) analyses.
For all comparisons, p values < 0.05 were considered statistically significant. Statistical analyses were performed using JMP Pro 16 (SAS Institute) and MATLAB 2020b (MathWorks).
Results
Study participants
MRI scans and PFT measurements were successfully performed in all 23 CF patients. Two out of 23 CF patients did not comply with N2-MBW measurement at the follow-up visit. Due to coronavirus pandemic-related restrictions, the follow-up measurement of seven out of 23 CF patients (30%) had to be postponed up to 19 weeks with one patient exception (28 weeks).
Effects of ETI therapy on MRI and associated lung function data
Therapy with ETI significantly improved all ventilation markers derived by 3D PREFUL MRI (range of improvement 1.9–28.1%, all p < 0.0056, Table 1) as well as MRI global, morphology, and perfusion scores (range of improvement 9.5–31.9%, all p < 0.02, Table 1), except for the 3D PREFUL–derived mean RVent parameter (improvement 0.6%, p = 0.16). As reported previously [15], FEV1, MEF25, and LCI significantly improved after therapy (range of improvement 22.4–74.7%, all p < 0.0001, Table 1). Representative 3D PREFUL ventilation parameters at baseline and post-ETI treatment initiation are depicted in Fig. 1. Treatment effects on 3D PREFUL ventilation parameters are depicted in Fig. 2.
Comparison of treatment changes between 3D PREFUL and lung function data
There was no significant correlation between absolute and relative treatment changes of 3D PREFUL MRI ventilation parameters (mean RVent, SD RVent, mean CC, SD CC, VDPRVent, and VDPCC) with FEV1, MEF25, LCI, and MRI scores (p > 0.05), except relative change of SD RVent parameter, which was significantly correlated with relative change of LCI (r = 0.48, p = 0.0275). Figure 3 shows regional TRMs derived by 3D PREFUL for two study participants. Looking only at positive changes in TRMs, the mean improved ventilation volume normalized to BSA was 147 (SD = 94) and 129 (SD = 114) mL/m2 for RVent (IVVRVent) and CC (IVVCC) parameters, respectively. The IVVRVent normalized to BSA was significantly correlated with relative treatment changes of MEF25 and mucus plugging MRI score (all |r| > 0.48, all p < 0.219, Table 2).
Comparison of post-treatment values between 3D PREFUL and lung function outcome parameters
In post-treatment analyses, 3D PREFUL–derived VDP values significantly correlated with spirometry, LCI, global score, morphology score, and perfusion score (all |r| > 0.44, all p < 0.0348, Table 3, Fig. 4), except for correlation of VDPCC with global and morphology score. CC values derived by 3D PREFUL correlated significantly with FEV1, MEF25, and LCI (all |r| > 0.49, all p < 0.0253, Table 3).
Discussion
This study assessed the effects of ETI therapy on pulmonary ventilation parameters derived by 3D PREFUL MRI in patients with CF. 3D PREFUL–derived ventilation parameters showed significantly reduced ventilation defects after initiation of ETI therapy and the improved ventilation volume measure was significantly correlated to the relative change in the morphological parameter mucus plugging and MEF25.
To our best knowledge, this is the first study to determine the effects of ETI therapy on pulmonary ventilation function using patient-friendly non-contrast-enhanced 3D MR acquisition during tidal breathing. As reported previously [15, 22], the improvements after initiation of ETI were also found for clinical outcome parameters, including spirometry and N2-MBW ventilation parameters, as well as for semi-quantitative MRI scores. Improved ventilation parameters after ETI therapy using dynamic perfluorinated gas 19F MR imaging have been previously reported in one study including 8 CF patients [23]. The authors revealed an absolute change difference of VDP values of −2.7% (relative change −33%), which is slightly lower compared to our results of −4.2% VDPRVvent (relative change −23%) and −4.4% VDPCC (relative change −46%). A direct comparison of our VDP values with mentioned 19F imaging VDP results is challenging due to different study design, signal generation differences, breathing conditions (free tidal breathing for 3D PREFUL vs. inspiration breath-hold for 19F), spatial resolution (4 x 4 x 4 mm3 for 3D PREFUL compared to 6.25 × 6.25 × 15 mm3 for 19F), and scanner field strengths (3D PREFUL at 1.5T vs. 19F at 3T).
As 3D PREFUL covers the whole lung volume, it is feasible to register pre- and post-treatment acquisitions and calculate treatment response ventilation maps, which enable a detailed longitudinal regional treatment change analysis [24]. Regarding relative treatment change, we found significant correlations of 3D PREFUL MRI–derived improved ventilation volume (IVVRVent normalized to BSA) with relative change of MEF25 and the mucus plugging MRI score. These findings suggest that reduced endobronchial mucus is predominantly responsible for regional ventilation improvement 8–16 weeks after initiation of ETI therapy. The positive changes in MRI-derived mucus plugging and wall thickening/bronchiectasis score have been shown to be associated with the improvement of CFTR function, which might reflect the resolution of inflammation in CF patients [15]. De Vuyst et al [25] demonstrated that the ETI therapy reduces airway inflammation in CF. Although 3D PREFUL MRI is not able to assess inflammation directly, the previous studies support the hypothesis that the improved regional ventilation derived by 3D PREFUL is related to the reduction in inflammation induced by ETI therapy. Also, the correlation of the regional ventilation changes with the relative change of MEF25 may indicate that 3D PREFUL MRI is sensitive to airflow changes in the small airways. This appears reasonable as 3D PREFUL MRI measures regional ventilation in the lung parenchyma. However, this finding warrants further investigation in future studies.
Absolute and relative changes of 3D PREFUL parameters were not directly correlated to changes in FEV1, LCI, and MRI scoring system. The missing correlations might be explained by the relatively small sample size leading to the low statistical power of our analysis. Also, this finding may highlight the complementary value of 3D PREFUL MRI and clinically established measures such as FEV1 and LCI.
Examining the relationship between 3D PREFUL parameters and other ventilation measures, significant correlations with post-treatment initiation FEV1, MEF25, LCI, global MRI score, morphology MRI score, perfusion MRI score, bronchial wall thickening/bronchiectasis MRI score, and mucus plugging score. The highest correlations were observed for dynamic cross-correlation parameter (CC and VDPCC), which uses the information of the whole respiratory cycle, with spirometric measures. This finding suggests increased treatment response sensitivity of CC when compared to static RVent parameters derived by 3D PREFUL. Nonetheless, the significant post-treatment correlations of 3D PREFUL ventilation measures especially with FEV1, LCI, and global MRI score demonstrate that 3D PREFUL MRI is sensitive to measure improved regional ventilation of the lung parenchyma due to reduced inflammation and endobronchial mucus in response to ETI therapy in CF patients. In addition, the improved perfusion score in the presented cohort may also be indicative of resolving inflammatory changes in the lung parenchyma post-ETI treatment.
In addition to the small sample size, we acknowledge further limitations. Firstly, the ventilation parameters derived by PREFUL (or other Fourier-decomposition-based methods) are considered indirect measures for ventilation. The key assumption of these methods is that the signal intensity variations of the lung parenchyma are induced by different lung volumes [6]. This idea has been validated for 2D PREFUL with direct 19F MRI and 129Xe ventilation measurement [26, 27] but not (yet) for 3D methods. Secondly, the repeatability of 3D PREFUL–derived dynamic parameters in CF patients has not been examined yet. Recent repeatability results in chronic obstructive pulmonary disease patients and stable CF patients showed no significant bias between repeated measurements of 3D and 2D PREFUL, respectively [14, 28]. This supports our results that the differences in 3D PREFUL parameters between baseline and post-treatment acquisition are a true response to ETI therapy. Additional useful information might be provided by assessment of improvement in ventilation on the lobar level, however was beyond the scope of this work. Future multicenter validation studies are necessary to investigate if 3D PREFUL MRI regional ventilation assessment may add value to current clinical standard techniques such as spirometry, N2-MBW, semi-quantitative thoracic MRI scores, or gas-based MRI techniques.
Conclusions
In summary, our study demonstrates that ETI therapy leads to improvement in lung ventilation determined by 3D PREFUL MRI in CF patients. Our data suggest that endobronchial mucus reduction is mainly responsible for regional ventilation improvement 8–16 weeks after initiation of ETI therapy.
Abbreviations
- ATS:
-
American Thoracic Society
- BLADE:
-
Periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER) in Siemens Healthcare MRI systems
- BSA:
-
Body surface area (m2)
- CC:
-
Cross-correlation (%)
- CF:
-
Cystic fibrosis
- CFTR:
-
Cystic fibrosis transmembrane conductance regulator
- CNN:
-
Convolutional neuronal network
- ERS:
-
European Respiratory Society
- FEV1 :
-
Forced expiratory volume in 1 s (% predicted value)
- FOV:
-
Field of view (cm2)
- GLI:
-
Global lung function initiative
- HASTE:
-
Half-Fourier acquisition single-shot turbo spin echo
- IVVCC :
-
Improved ventilation volume derived from TRMCC (mL)
- IVVRVent :
-
Improved ventilation volume derived from TRMRVent (mL)
- LCI:
-
Lung clearance index
- MEF25:
-
Mid-expiratory flow at 25% of forced vital capacity (% predicted value)
- N2-MBW:
-
Nitrogen multiple-breath washout
- PFT:
-
Pulmonary functional testing
- PREFUL:
-
Phase-resolved functional lung
- RVent:
-
Regional ventilation (mL/mL)
- TE:
-
Echo time (ms)
- TR:
-
Repetition time (ms)
- TRMCC :
-
Treatment response map based on VDPCC
- TRMRVent :
-
Treatment response map based on VDPRVent
- VDPCC :
-
Ventilation defect percentage value based on CC (%)
- VDPRVent :
-
Ventilation defect percentage value based on RVent (%)
- VIBE:
-
Volumetric interpolated breath-hold examination
References
O’Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373:1891–1904. https://doi.org/10.1016/S0140-6736(09)60327-5
Burgel PR, Durieu I, Chiron R et al (2021) Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med 204:64–73. https://doi.org/10.1164/rccm.202011-4153OC
Nichols DP, Paynter AC, Heltshe SL et al (2022) Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis a clinical trial. Am J Respir Crit Care Med 205:529–539. https://doi.org/10.1164/rccm.202108-1986OC
Barry PJ, Mall MA, Álvarez A et al (2021) Triple therapy for cystic fibrosis Phe508del –gating and –residual function genotypes. N Engl J Med 385:815–825. https://doi.org/10.1056/nejmoa2100665
Ramsey KA, Rosenow T, Turkovic L et al (2016) Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis. Am J Respir Crit Care Med 193:60–67. https://doi.org/10.1164/rccm.201507-1409OC
Zapke M, Topf H-G, Zenker M et al (2006) Magnetic resonance lung function – a breakthrough for lung imaging and functional assessment? A phantom study and clinical trial. Respir Res 7:106. https://doi.org/10.1186/1465-9921-7-106
Bauman G, Puderbach M, Deimling M et al (2009) Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of Fourier decomposition in proton MRI. Magn Reson Med 62:656–664. https://doi.org/10.1002/mrm.22031
Fischer A, Weick S, Ritter CO et al (2014) SElf-gated Non-Contrast-Enhanced FUnctional Lung imaging (SENCEFUL) using a quasi-random fast low-angle shot (FLASH) sequence and proton MRI. NMR Biomed 27:907–917. https://doi.org/10.1002/nbm.3134
Voskrebenzev A, Gutberlet M, Klimeš F et al (2018) Feasibility of quantitative regional ventilation and perfusion mapping with phase-resolved functional lung (PREFUL) MRI in healthy volunteers and COPD, CTEPH, and CF patients. Magn Reson Med 79:2306–2314. https://doi.org/10.1002/mrm.26893
Bauman G, Bieri O (2017) Matrix pencil decomposition of time-resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion. Magn Reson Med 77:336–342. https://doi.org/10.1002/mrm.26096
Klimeš F, Voskrebenzev A, Gutberlet M et al (2021) 3D phase-resolved functional lung ventilation MR imaging in healthy volunteers and patients with chronic pulmonary disease. Magn Reson Med 85:912–925. https://doi.org/10.1002/mrm.28482
Mendes Pereira L, Wech T, Weng AM et al (2018) UTE-SENCEFUL: first results for 3D high-resolution lung ventilation imaging. Magn Reson Med 1–10. https://doi.org/10.1002/mrm.27576
Boucneau T, Fernandez B, Larson P et al (2020) 3D magnetic resonance spirometry. Sci Rep 10:1–12. https://doi.org/10.1038/s41598-020-66202-7
Klimeš F, Voskrebenzev A, Gutberlet M et al (2021) Repeatability of dynamic 3D phase-resolved functional lung (PREFUL) ventilation MR Imaging in patients with chronic obstructive pulmonary disease and healthy volunteers. J Magn Reson Imaging 54:618–629. https://doi.org/10.1002/jmri.27543
Graeber SY, Renz DM, Stahl M et al (2022) Effects of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med 206:311–320. https://doi.org/10.1164/rccm.202201-0219OC
Eichinger M, Optazaite DE, Kopp-Schneider A et al (2012) Morphologic and functional scoring of cystic fibrosis lung disease using MRI. Eur J Radiol 81:1321–1329. https://doi.org/10.1016/j.ejrad.2011.02.045
Klimeš F, Voskrebenzev A, Gutberlet M et al (2022) Evaluation of image registration algorithms for 3D phase‐resolved functional lung ventilation magnetic resonance imaging in healthy volunteers and chronic obstructive pulmonary disease patients. NMR Biomed 0–3. https://doi.org/10.1002/nbm.4860
Klimeš F, Voskrebenzev A, Gutberlet M et al (2019) Free-breathing quantification of regional ventilation derived by phase-resolved functional lung (PREFUL) MRI. NMR Biomed 32:e4088. https://doi.org/10.1002/nbm.4088
Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338. https://doi.org/10.1183/09031936.05.00034805
Quanjer PH, Stanojevic S, Cole TJ et al (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324–43. https://doi.org/10.1183/09031936.00080312
Robinson PD, Latzin P, Verbanck S et al (2013) Consensus statement for inert gas washout measurement using multiple- and singlebreath tests. Eur Respir J 41:507–522. https://doi.org/10.1183/09031936.00069712
Wucherpfennig L, Triphan SMF, Wege S et al (2022) Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. J Cyst Fibros. https://doi.org/10.1016/j.jcf.2022.03.011
Goralski JL, Chung SH, Ceppe AS et al (2022) Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after elexacaftor/tezacaftor/ivacaftor: an observational study. J Clin Med 11:6160. https://doi.org/10.3390/jcm11206160
Horn FC, Marshall H, Collier GJ et al (2017) Regional ventilation changes in the lung: treatment response mapping by using hyperpolarized gas MR imaging as a quantitative biomarker. Radiology 284:854–861. https://doi.org/10.1148/radiol.2017160532
De Vuyst RC, Bennard E, Kam CW et al (2023) Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatr Pulmonol 0–3. https://doi.org/10.1002/ppul.26334
Kaireit TF, Gutberlet M, Voskrebenzev A et al (2018) Comparison of quantitative regional ventilation-weighted Fourier decomposition MRI with dynamic fluorinated gas washout MRI and lung function testing in COPD patients. J Magn Reson Imaging 47:1534–1541. https://doi.org/10.1002/jmri.25902
Kaireit TF, Kern A, Voskrebenzev A et al (2021) Flow volume loop and regional ventilation assessment using phase-resolved functional lung (PREFUL) MRI: comparison with 129Xenon ventilation MRI and lung function testing. J Magn Reson Imaging 53:1092–1105. https://doi.org/10.1002/jmri.27452
Munidasa S, Zanette B, Couch M et al (2022) Inter- and intravisit repeatability of free-breathing MRI in pediatric cystic fibrosis lung disease. Magn Reson Med. https://doi.org/10.1002/mrm.29566
Acknowledgements
The authors would like to acknowledge Melanie Pfeifer, Frank Schröder, and Sven Thiele from the Department of Radiology (Hannover Medical School, Germany) for excellent experimental support.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was funded by the German Center for Lung Research (DZL) and supported by Siemens Healthcare GmbH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Jens Vogel-Claussen.
Conflict of interest
Filip Klimeš, Andreas Voskrebenzev, and Jens Vogel-Claussen are shareholders in BioVisioneers GmbH, a company, which has interest in pulmonary magnetic resonance imaging methods.
Robert Grimm is an employee of Siemens Healthcare GmbH, Erlangen, Germany.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional Review Board approval was obtained.
Study subjects or cohorts overlap
Some study subjects or cohorts have been previously reported in Graeber et al (2022) American Journal of Respiratory and Critical Care Medicine, https://doi.org/10.1164/rccm.202110-2249OC.
Methodology
-
prospective
-
observational
-
performed at one institution
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Klimeš, F., Voskrebenzev, A., Gutberlet, M. et al. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients. Eur Radiol 34, 80–89 (2024). https://doi.org/10.1007/s00330-023-09912-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-09912-6